News | May 04, 2024
Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Open a printable version of this pageEmail the URL of this page to a friend
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
